|
1) Day CP, James OF. Steatohepatitis: a tale of two “hits"？ Gastroenterology. 1998; 114: 842-5
|
|
|
|
2) Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009; 49: 306-17
|
|
|
|
|
3) Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297-307
|
|
|
|
|
|
4) Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135: 1176-84
|
|
|
|
|
|
5) Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38: 1008-17
|
|
|
|
|
|
6) Ratziu V, Giral P, Jacquenminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135: 100-10
|
|
|
|
|
|
7) Angelico F, Burartin M, Alessandri C, et al. Dugs improving insulin resistance for non-alcoholic fatty liver disease and /or non-alcoholic steatohepatitis. Cohrane Database Syst Rev. 2007; CD005166
|
|
|
|
|
|
8) Knowler WC, Barrett-Connot E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403
|
|
|
|
|
|
9) Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009; 49: 80-6
|
|
|
|
|
|
10) Gaedeke J, Peters H, Noble NA, et al. Angiotensin II, TGF-β and renal fibrosis. Contrib Nephrol. 2001; 135: 153-60
|
|
|
|
|
|
11) Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001; 34: 745-50
|
|
|
|
|
|
12) Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004; 40: 1222-5
|
|
|
|
|
|
13) Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007; 45: 1375-81
|
|
|
|
|
|
14) Georegescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option？ Adv Ther. 2008; 25: 1141-74
|
|
|
|
|
|
15) Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediat. 2000; 136: 734-8
|
|
|
|
|
|
16) Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther. 2001; 15: 1667-72
|
|
|
|
|
|
17) Harrison T, Torgerson S, Hayashi P, et al. Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98: 2485-90
|
|
|
|
|
|
18) Balmer ML, Siegrist K, Zimmermann A, et al. Effects of urosdeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liv Inter. 2009; 29: 1184-8
|
|
|
|
|
|
19) Sumida Y, Kanemasa K, Fukumoto K, et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res. 2006; 36: 315-21
|
|
|
|
|
20) Tessier DJ, Eagon JC. Surgical management of morbid. Curr Probl Surg. 2008; 45: 68-137
|
|
|
|
|
|
21) Braghetto I, Korn O, Valladares H, et al. Laparoscopic sleeve gastrectomy: surgical technique, indications and clinical results. Obes Surg. 2007; 17: 1442-50
|
|
|
|
|
|
22) Mummadi R, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease (NAFLD): systemic review and meta-analysis. Clin Gastroenterol Hepatol. 2008; 6: 1396-40
|
|
|
|
|
|
23) 肥満症治療ガイドライン作成委員会. 肥満症治療ガイドライン V. 治療の実際. 肥満研究. 2006; 12(臨増): 18-41
|
|
|
|
|